Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 5Thoracic 1Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms 2Small Cell Lung Carcinoma 1Rectal Neoplasms 1Pancreatic Neoplasms 1Lung Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Ovarian Epithelial 1Breast Neoplasms, Male 1

Interventions

Paclitaxel 12pembrolizumab 7Carboplatin 7Cisplatin 6Docetaxel 5sargramostim 4Taxes 4Cyclophosphamide 4Amifostine 4Trastuzumab 3Polymerase Chain Reaction 3Nivolumab 3Irinotecan 3Gemcitabine 3Etoposide 3talazoparib 2aldesleukin 2Vorinostat 2Vinorelbine 2SS1(dsFv)PE38 2Pemetrexed 2Interleukin-12 Subunit p35 2Interleukin-12 2Immunoenzyme Techniques 2Gene Expression Profiling 2Flow Cytometry 2Filgrastim 2Erlotinib Hydrochloride 2tocilizumab 1tislelizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Ovarian Epithelial × denileukin diftitox × Thoracic × Clear all
NCT00228358 2014-11-11

Cyclophosphamide or Denileukin Diftitox Followed By Expanding a Patient's Own T Cells in the Laboratory in Treating Patients With HER-2/Neu Overexpressing Metastatic Breast Cancer, Ovarian Cancer, or Non-Small Cell Lung Cancer Previously Treated With HER-2/Neu Vaccine

University of Washington

Phase 1 Completed
8 enrolled
BreastGynecologicThoracic

Carcinoma, Ovarian Epithelial, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡